Mer­ck­'s Welireg meets co-pri­ma­ry end­point in kid­ney can­cer PhI­II; Noveome rais­es half of planned $40M VC round

Mer­ck said Fri­day morn­ing that its HIF-2α in­hibitor Welireg met the co-pri­ma­ry end­point of pro­gres­sion-free sur­vival in a Phase III tri­al for pa­tients with ad­vanced forms of re­nal cell car­ci­no­ma, but it did not meet the oth­er co-pri­ma­ry end­point of over­all sur­vival.

The topline da­ta come from a head-to-head Phase III tri­al with everolimus, al­so known as No­var­tis’ Afin­i­tor, test­ing Welireg in pre-treat­ed pa­tients with ad­vanced forms of re­nal cell car­ci­no­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER